

Experimental & Molecular Medicine

Guide for Authors

About the Journal	1
Article Type Specifications	2
Preparation of Articles	2
How to Submit	6
Post-Acceptance	7
Editorial Policies	7
Further information	12

ABOUT THE JOURNAL

Aims and Scope

Experimental & Molecular Medicine is a medical research journal devoted to publishing the latest developments in translational research and the recent discoveries in the biomedical field. Submission is encouraged of papers that involve genetic, molecular and cellular studies of human physiology and diseases. The journal seeks to highlight the improved clinical benefits for human health from experimental and translational research performed using specific molecular tools. Studies that encompass basic discoveries with clinical relevance as well as articles dealing with clear in vivo relevance and novelty will also be welcomed. *Experimental & Molecular Medicine* is an open access, online-only journal.

Topics of particular interest within the journal's scope include, but are not limited to, those listed below:

- Cancer biology
- Immunology
- Neuroscience
- Cardiovascular biology
- Genetics and genomics
- Gene therapy
- Metabolic diseases
- Stem cells and regenerative medicine

The journal publishes peer-reviewed Original Articles, Reviews and Correspondences. In addition, Research Summaries are provided for selected articles.

Journal Details

Editor-in-Chief:

Dae-Myung Jue
Professor, Department of Biochemistry
Catholic University of Korea

Editorial office:

The *Experimental & Molecular Medicine* Editorial Office
The Korean Federation of Science and Technology Societies Building
Room #801
22, 7 Gil, Teheran-ro, Gangnam-gu,
Seoul 06130
South Korea
Email: ksmb3@ksbmb.or.kr

Impact factor:

12.8 (2022 *Journal Citation Reports*, Thomson Reuters, 2023)

Abstracted in:

Google Scholar
Science Citation Index & Biological Abstracts (ISI – Thomas Reuters)

MEDLine (PubMed)
 Chemical Abstract Services (CAS)
 EM Base (Elsevier Scopus)

ARTICLE TYPE SPECIFICATIONS

Experimental and Molecular Medicine publishes:

- **Articles**
 Articles describe original research, and should not exceed 6,000 words (excluding the abstract, tables, figure legends and references) and 6–8 display items.
- **Reviews**
 Reviews cover a focused area on the advancing fields of biomedical research and provide a balanced view of current research that can be understood by researchers outside that specialty. They should be succinctly written and not exceed 6,000 words.
 Reviews can be structured using short topical headings. Reviews can be submitted directly by authors or be solicited by the editors. Authors interested in writing a Review may submit a proposal, including an outline of the proposed article, by email to the [Editorial Office](#). All Reviews are subject to peer-review.
- **Correspondences**
 The Correspondence section provides readers with a forum for comment on papers published in a previous issue of the journal, or to discuss anything of interest to the journal's readers, from policy debates to announcements to matters arising in the relevant area. A Correspondence should typically 250-500 words. The number of references should not exceed 10. Titles for correspondence are supplied by the editors. In cases where a correspondence is critical of a previous research paper, the authors are given the option of publishing a brief reply. Correspondences are reviewed by the editor and may be peer reviewed at the editor's discretion.

Manuscript layout guideline for each article type

Article Type	Abstract	Word Count	Main text components	Display Items	References
Article	250 words	6,000	Title Page/Introduction/ Materials and methods/ Results/ Discussion/ Acknowledgements/ Conflict of interest (if applicable)/ References	Up to 8 display items (e.g. figures, tables) to be prepared in separate files.	60
Review Article	250 words	6,000	Title Page/Introduction (if applicable)/ Main text/ Acknowledgements/Conflict of interest (if applicable) / References	Up to 8 display items (e.g. figures, tables) to be prepared in separate files	100
Editorial (solicited)	N/A	1,500	No sections	N/A	20
Correspondence	N/A	250-500	Main text/Conflict of Interest (if applicable) / References	N/A	10

PREPARATION OF ARTICLES

Organization of Manuscript

Manuscripts should be presented in the following order (omitting sections inappropriate for specific article types e.g. Methods for Reviews): (i) Title page, (ii) Abstract, (iii) Introduction, (iv) Materials and Methods, (v) Results, (vi) Discussion, (vii) Acknowledgements, (viii) References, (ix) Appendices, (x) Figure legends, (xi) Tables (each table complete with title and footnotes) and (xii) Figures. Footnotes to the text are not allowed and any such material should be incorporated into the text as parenthetical matter.

Please see below for details of the manuscript components.

Cover Letter: Cover letter should be attached to all article types. The uploaded covering letter must state the material is original, has not been previously published and has not been submitted for publication elsewhere while under consideration. If the

manuscript has been previously considered for publication in another journal, please include the previous reviewer comments, to help expedite the decision by the Editorial team. Please also include the following information;

- The name, institution and e-mail address of all contributing authors
- Suggestions for at least 3 potential referees, including contact information if known (This information will be requested during the electronic submission process.)
- Referees to exclude (optional)
- Conflict of interest statement for all authors

Title Page: The title page should bear the title of the paper, the full names of all the authors and their affiliations, together with the name, full postal address, telephone and e-mail address of the author to whom correspondence are to be sent (this information is also asked for on the electronic submission form).

- Total number of words
- Authors should disclose the sources of any support for the work, received in the form of grants and/or equipment and drugs.
- If authors regard it as essential to indicate that two or more co-authors are equal in status, they may be identified by an asterisk symbol with the caption 'These authors contributed equally to this work' immediately under the address list.

Abstract: The abstract should be comprehensible to readers before they have read the paper. Abbreviations and reference citations within the abstract should be avoided.

Introduction: This should give a short, clear account of the background and reasons for undertaking the study. The Introduction should assume that the reader is knowledgeable in the field and should therefore be as brief as possible.

Materials and Methods: This section should contain sufficient detail so that all experimental procedures can be repeated by others, in conjunction with cited references. This section may be divided into subheadings to assist the reader.

Novel experimental procedures should be described in detail, but published procedures should be referred to by literature citation of the original article and published modifications. Authors should provide the name of the manufacturer for any specifically named equipment and instruments; if applicable, all drugs should be identified by their pharmaceutical names, and by their trade name if relevant. The source of cells utilized and where information about them (species, strain, sex, race, age of donor) can be obtained should be clearly indicated. If there is no open data source for the cells, the information should be described.

Experimental and Molecular Medicine strongly encourages that all datasets on which the conclusions of the paper rely should be available to readers. We encourage authors to ensure that their datasets are either deposited in publicly available repositories (where available and appropriate) or presented in the main manuscript or additional supporting files whenever possible. Please see Springer Nature's information on [recommended repositories](#). General repositories - for all types of research data - such as Figshare and Dryad may be used where appropriate.

Results: The description of results should not simply reiterate data that appear in tables and figures and, likewise, the same data should not be displayed in both tables and figures. The results section should be concise and follow a logical sequence. If the paper describes a complex series of experiments, it is permissible to explain the protocol/experimental design before presenting the results. Do not discuss the results or draw any conclusions in this section. This section may be divided into subheadings to assist the reader. Large datasets or other cumbersome data pertinent to the manuscript may be submitted as supplementary information.

Discussion: Do not recapitulate the results, but discuss their significance against the background of existing knowledge, and identify clearly those aspects that are novel. The final paragraph should highlight the main conclusion(s), and provide some indication of the direction future research should take.

Acknowledgements: These should be brief, and should include sources of financial support, material (e.g. novel compounds, strains, etc.) not available commercially, personal assistance, advice from colleagues and gifts.

Conflict of Interest: Authors must declare whether or not there are any competing financial interests in relation to the work described. This information must be included at this stage and will be published as part of the paper. Conflict of Interest should be noted in the cover letter and in the paper. Please see the Conflict of Interest documentation in the [Editorial Policy](#) section for detailed information.

References: Authors are responsible for the accuracy of the references. Only papers directly related to the article should be cited; exhaustive lists of related reading should be avoided. All authors should be included in reference lists unless there are six or more, in which case only the first author should be given, followed by 'et al'. In the text of the manuscript, references to the literature should be numbered consecutively and indicated by a superscript. Each reference should be numbered individually

and listed at the end of the manuscript.

The reference list should be double-spaced, and there should be only one reference per number. Only articles that have been published or accepted and waiting for publication (listed as 'in press' following digital object identifier number) should be in the reference list. Reference to 'unpublished data' and 'personal communications' should not appear in the list but should be cited in the text parenthetically only (e.g. Smith A, 2007, unpublished data). Written proof for 'personal communication' and preprint for 'in press' may be requested for review. Journal names are italicized and abbreviated (with full stops) according to the Web of Science Journal Title Abbreviations or Chemical Abstracts Service CPlus Core Journal Coverage List.

Number	Type	Example
1.	Journal article with two authors	Gredmark, T. & Hallberg, L. Population study of women in Goteburg. <i>Scand. J. Soc. Med.</i> 6 , 51-54 (1978).
2.	Journal article with five authors	Price, R. A. Jr, Curry, N. III, McCann, K. E., Fielding, J. L. & Abercrombie, E. Jr. Analysis of obesity in twins. <i>Hum. Hered.</i> 39 (Suppl.), 121-135 (1989).
3.	Journal article with more than six authors	Halpern S.D. <i>et al.</i> Solid-organ transplantation in HIV-infected patients. <i>N. Engl. J. Med.</i> 347 , 284-287 (2002).
4.	Article by DOI (without page numbers)	He, F. J., Marrero, N. M. & MacGregor, G. A. Salt and blood pressure in children and adolescents. <i>J. Hum. Hypertens.</i> https://doi.org/10.1038/sj.jhh.1002269 (2007).
5.	Article in electronic journal without DOI (no paginated version)	Hill, W. G., Goddard, M. E. & Visscher, P. M. Data and theory point to mainly additive genetic variance for complex traits. <i>PLoS Genet.</i> 4 , e1000008 (2008).
6.	Published abstract	Feig, S. A. <i>et al.</i> Bone marrow transplantation for neuroblastoma. <i>Exp. Hematol.</i> 13 , abstr. 102 (1985).
7.	Publicly available preprint	Babichev, S. A., Ries, J. & Lvovsky, A. I. Quantum scissors: teleportation of single-mode optical states by means of a nonlocal single photon. Preprint at http://arXiv.org/quant-ph/0208066 (2002).
8.	Book (monograph)	Meyer, H. A. <i>The Role of Abdominal Fat</i> 2nd edn, Vol. 2 (Academic, New York, 1970).
9.	Book (edited volume)	Diener, B. J. & Wilkinson, P. (eds) <i>Transplantation Techniques</i> (Harvard Univ. Press, Cambridge, 1989).
10.	Book chapter	Harley, N. H. & Vivian, L. in <i>Mechanisms of Disease</i> 4th edn, Vol. 2 (eds Sodeman, W. A. & Smith, A.) Ch. 3 (Saunders, Philadelphia, 1974).
11.	Published conference proceedings	Smith, Y. (ed.) <i>Proc. 1st National Conference on Porous Sieves</i> (Butterworth-Heinemann, London, 1997).
12.	Paper in published conference proceedings	Jones, X. Zeolites and synthetic mechanisms. In <i>Proc. 1st National Conference on Porous Sieves</i> (ed. Smith, Y.) 16-27 (Butterworth-Heinemann, London, 1997).
13.	Dissertation	Young, W. R. <i>Effects of Different Tree Species on Soil Properties in Central New York</i> . MSc thesis, Cornell Univ. (1981).
14.	Retracted article (including retraction information)	Caddy, S. G. <i>et al.</i> Growth of limpets on the rocky shore. <i>Nature Genet.</i> 3 , 426-431 (1995); retraction 4 , 104 (1996).
15.	Retraction note to article	Caddy, S. G. <i>et al.</i> Retraction: Growth of limpets on the rocky shore. <i>Nature Genet.</i> 4 , 104 (1996).
16.	Scientific technical report	Akutsu, T. <i>Total Heart Replacement Device</i> . Report No. NIH-NHLI-69 2185-4 (National Institutes of Health, Bethesda, 1974).
17.	Article with published erratum	Johnson, P., Ing-Simmons, C. H. R., Bennett, P., Adams, S. & Freeman, A. The effect of fire on the Lundy cabbage. <i>West. Eng. J.</i>

		162 , 28–31 (1999); erratum 162 , 3127 (1999).
18.	Online material (Blog)	Manaster, J. Sloth squeak. <i>Scientific American Blog Network</i> http://blogs.scientificamerican.com/psivid/2014/04/09/slothsqueak (2014).
19.	Software	SAS v.8 (SAS Institute Inc., 2000).
20.	Patent	Pagedas, A. C. Reusable laparoscopic retrieval mechanism. US patent 6, 387, 102 (2002).

Please follow the style below in the published edition of *Experimental & Molecular Medicine* in preparing reference lists.

- Authors should be listed surname first, followed by a comma and initials of given names.
- **Titles of all cited articles are required.** Titles of articles cited in reference lists should be in upright, not italic text; the first word of the title is capitalized, the title written exactly as it appears in the work cited, ending with a full stop. Book titles are italic with all main words capitalized. Journal titles are italic and abbreviated according to common usage. Volume numbers are bold. The publisher and city of publication are required for books cited. (Refer to published papers in *Experimental & Molecular Medicine* for details.)
- Research datasets may be cited in the reference list if they have been assigned digital object identifiers (DOIs) and include authors, title, publisher (repository name), identifier (DOI expressed as a URL). Example: Hao, Z., AghaKouchak, A., Nakhjiri, N. & Farahmand, A. Global Integrated Drought Monitoring and Prediction System (GIDMaPS) data sets. figshare <http://dx.doi.org/10.6084/m9.figshare.853801> (2014).
- Recognized preprints may be cited in the reference list. Example: Babichev, S. A., Ries, J. & Lvovsky, A. I. Quantum scissors: teleportation of single-mode optical states by means of a nonlocal single photon. Preprint at <http://arXiv.org/quant-ph/0208066> (2002).
- References to web-only journals should give authors, article title and journal name as above, followed by URL in full - or DOI if known - and the year of publication in parentheses.
- References to websites should give authors if known, title of cited page, URL in full, and year of posting in parentheses.

End Notes: End notes are brief and follow the reference list. Please refer to our [annotated example](#) to see how they appear in an *Experimental & Molecular Medicine* paper

Figures: Figures and images should be labeled sequentially and cited in the text. Each panel in the figure should be labeled in lower case letters. Figures should not be embedded within the text but rather uploaded as separate files. Figure legends should be submitted on a separate sheet with list of text captions to all figures. Detailed guidelines for submitting artwork can be found by downloading our [Artwork Guidelines](#). The use of three-dimensional histograms is strongly discouraged when the addition of the third dimension gives no extra information. If a table or figure has been published before, the authors must obtain written permission to reproduce the material in both print and electronic formats from the copyright owner and submit it with the manuscript. This follows for quotes, illustrations and other materials taken from previously published works not in the public domain. The original source should be cited in the figure caption or table footnote.

Key Notes on Figures

- Recommended minimum resolution: 300 dpi for colour, 600 dpi for grey scale, 1000 dpi for line art
- Lines should be no thinner than 0.5 point in the actual size.
- Use sans serif typefaces such as Arial or Helvetica in your artwork and when labelling panels.
- Lettering should be no smaller than 6 points in the actual size; size of lettering should be uniform throughout the figure.
- Please refer to the Artwork Guidelines for details of artwork preparation.

Figure Legends: These should be brief, specific and appear on a separate manuscript page after the References section.

File Format for Artworks

For Figures, we prefer to use TIFF and EPS files in PC format, preferably from Photoshop or Illustrator software. We can also accept Adobe, native PowerPoint, Word and Excel files, provided that each figure element is editable.

For Tables, please submit tables in (editable) Word or Excel* format. Please avoid setting Table rows in picture format and then saving the document in Word.

*Please ensure any MS Office 2007 files are set to 'compatibility mode' (97 - 2003).

Graphs, Histograms and Statistics

- Error bars must be described in the figure legend
- Axes on graphs should extend to zero, except for log axes
- Statistical analyses (including error bars and p values) should only be shown for independently repeated experiments, and must not be shown for replicates of a single experiment
- The number of times and experiment was repeated (N) must be stated in the legend

Tables: These should be labelled sequentially and cited within the text. Each table should be presented on its own page, numbered and titled. Reference to table footnotes should be made by means of Arabic numerals. Tables should not duplicate the content of the text. They should consist of at least two columns; columns should always have headings. Authors should ensure that the data in the tables are consistent with those cited in the relevant places in the text, totals add up correctly, and percentages have been calculated correctly.

Unlike figures or images, tables may be embedded into the word processing software if necessary, or supplied as separate electronic files.

Graphical Abstract (optional): A graphical abstract, which summarizes the manuscript in a visual way, is designed to attract the attention of readers to the table of contents of the journal. Graphical abstracts are published with Original Articles and Reviews. The graphical abstract may contain chemical structures or images. The graphic should be submitted as a single file using a standard file format (see below). All graphical abstracts should be submitted with a white background and imagery should fill the available width, whenever possible. Please see artwork guidelines for the resolution requirements of the graphic. Graphical abstracts should be accompanied by a textual caption summarizing the main findings of the work in less than 100 words. Please submit file as Figure file and title as Graphical abstract when uploading to the submission system.

Supplementary Information: Supplementary information (SI) is peer reviewed material directly relevant to the conclusion of an article that cannot be included in the article owing to format constraints. The article must be complete and self-explanatory without the SI, which is posted on the journal's website and linked to the article. SI may consist of data files, graphics, movies or extensive tables. Please see our [Artwork Guidelines](#) for information on accepted file types.

Authors should ensure that supplementary information is supplied in its FINAL format because it is not subedited and will appear online exactly as submitted. It can neither be altered, nor added to, after the paper has been accepted for publication. Please supply the supplementary information via eJP, the electronic manuscript submission and tracking system, in an acceptable file format (see below).

When submitting SI, authors are required to:

- Include a text summary (no more than 50 words) to describe the contents of each file.
- Identify the types of files (file formats) submitted.
- Include the text "Supplementary information is available at (journal name)'s website" at the end of the article and before the references.
- Include the text 'Supplementary information accompanies the manuscript on the Experimental & Molecular Medicine' website (<http://www.nature.com/emm/>)' at the end of the article and before the references.

Accepted file formats

- Quick Time files (.mov)
- Graphical image files (.gif)
- MPEG movie files (.mpg)
- JPEG image files (.jpg)
- Image tiff files (.tiff)
- Video avi (.avi)
- Sound files (.wav)
- Plain ASCII text (.txt)
- Acrobat files (.pdf)

- MS Word documents (.doc)
- Postscript files (.ps)
- MS Excel spreadsheet documents (.xls)
- PowerPoint (.ppt)
- ChemDraw (.cdx)
- Tex, Latex (.tex)

File sizes must be as small as possible, so that they can be downloaded quickly. Images should not exceed 640 x 480 pixels (9 x 6.8 inches at 72 pixels per inch), but we would recommend 480 x 360 pixels as the maximum frame size for movies. We would also recommend a frame rate of 15 frames per second. If applicable to the presentation of the supplementary information, use a 256-color palette. Please consider the use of lower specification for all of these points if the supplementary information can still be represented clearly. Our recommended maximum data rate is 150 KB/s.

The number of files should be limited to eight, and the total file size should not exceed 8 MB. Individual files should not exceed 1 MB. Please seek advice from the editorial office before sending files larger than the allowed maximum size to avoid delays in publication.

Further questions about the submission or preparation of supplementary information should be directed to the editorial office.

House Style

As the electronic submission will provide the basic material for typesetting, it is important that papers are prepared in the general editorial style of the journal.

- See the Artwork Guidelines PDF for information on labelling of figures and line weights
- Use a coarse hatching pattern rather than shading for tints in graphs
- Color should be distinct when being used as an identifying tool
- Use SI units throughout
- Spaces, not commas should be used to separate thousands
- Abbreviations should be preceded by the words for which they stand in the first instance of use and should not be used for terms used fewer than 4 times. Very common abbreviations such as FFA, RNA, need not be defined. Note these abbreviations: gram g; litre l; milligram mg; kilogram kg; kilojoule kJ; megajoule MJ; weight wt; seconds s; minutes min; hours h. Do not add s for plural units.
- Text should be double spacing with a wide margin
- If you submit raw data, this can be done in Excel, or tab/comma delimited format
- At first mention of a manufacturer the town, (state if USA) and country should be provided.

Language Editing

Authors who are not native speakers of English sometimes receive negative comments from referees or editors about the language and grammar usage in their manuscripts, which can contribute to a paper being rejected.

To reduce the possibility of such problems, we strongly encourage such authors to take at least one of the following steps:

- Have your manuscript reviewed for clarity by a colleague whose native language is English.
- Review the tips for technical writing here: http://www.nature.com/authors/author_resources/how_write.html.
- Use an English language editing service such as [Nature Research Editing Service](#). An editor will improve the English to ensure that your meaning is clear and to identify problems that require your review.

Please note that the use of a language editing service is at the author's own expense and does not guarantee that the article will be selected for peer review or accepted.

File Formats

Use a common word-processing package (such as Microsoft Word) for the text. Please follow Artwork Guidelines below for preparation of figure files. Further advice on file types is also available from the Tips web page.

Saving files with Microsoft Office 2007 or higher.

Microsoft Office 2007 saves files in an XML format by default (file extensions .docx, .pptx and .xlsx). Files saved in this format cannot be accepted for publication.

Save Word documents using the file extension .doc

- Select the Office Button in the upper left corner of the Word 2007 Window and choose "Save As"
- Select "Word 97-2003 Document"
- Enter a file name and select "Save"

These instructions also apply for the new versions of Excel and PowerPoint.

Equations in Word must be created using Equation Editor 3.0

Equations created using the new equation editor in Word 2007 and saved as a "Word 97-2003 Document" (.doc) are converted to graphics and can no longer be edited. To insert or change an equation with the previous equation editor:

- Select "Object" on the "Text" section of the "Insert" tab
 - In the drop-down menu, select "Equation Editor 3.0"
- Do not use the "Equation" button in the "Symbols" section of the "Insert" tab.

HOW TO SUBMIT

Pre-submission Enquiries

Please submit via our online manuscript submission system or via e-mail to [EMM Editorial office](#).

Online Submission

We only accept manuscript submission via our online manuscript submission system. Before submitting a manuscript, authors are encouraged to consult both our [Editorial Policies](#) and the [Submission Instructions](#) for our online manuscript submission system. If you have not already done so, please [register for an account](#) with our online manuscript system. You will be able to monitor the status of your manuscript online throughout the editorial process.

Submission of Revisions

Authors submitting a revised manuscript after review are asked to include the following:

- (1) A rebuttal letter, indicating point-by-point how you have addressed the comments raised by the reviewers. If you disagree with any of the points raised, please provide adequate justification in your letter.
- (2) A marked-up version of the manuscript that highlights changes made in response to the reviewers' comments in order to aid the Editors and reviewers. Do not use track changes or comments.
- (3) A 'clean' (non-highlighted) version of the revised manuscript.

POST-ACCEPTANCE

Experimental and Molecular Medicine is an open access journal: authors pay an article processing charge (APC) for their accepted articles to be open access online and freely accessible, immediately upon publication, under a Creative Commons license. Members of the Korean Society for Biochemistry and Molecular Biology are eligible for a 20% discount on the article-processing charge and further details are supplied in the acceptance letter.

Visit our open research site for further information about licenses, APCs, and our free OA funding support service:

- [About Creative Commons licensing](#)
- [Creative Commons license options and article processing charges \(APCs\) for *Experimental and Molecular Medicine*](#)
- [APC payment FAQs](#)
- [Help in identifying funding for APCs](#)
- [APC waiver policy](#)
- [Compliance with funding body requirements](#)

Upon acceptance of their manuscript it is mandatory for authors to complete the Article Processing Charge form and licence to publish form via our online portals; processing of an accepted manuscript can only proceed once these forms have been completed. *Experimental & Molecular Medicine* articles are published under a Creative Commons Attribution 4.0 International License (CC BY 4.0). More information on licence and user rights can be found on the [open access page](#).

Government employees from the United States, UK, and Canada are required to sign and submit the relevant government open access licence to publish form.

Please note with regards to payment that usual credit terms are 30 days from receipt of invoice. Failure to pay your invoice within the stated credit term may result in such penalties as restrictions on your ability to publish with Springer Nature or *Experimental & Molecular Medicine* in the future, involvement of a third party debt collection agency and legal proceedings.

Manuscript Deposition and Self-Archiving

To facilitate self-archiving Springer Nature deposits open access articles in PubMed Central and Europe PubMed Central on publication. Authors are also permitted to post the final, published PDF of their article on a website, institutional repository or other free public server, immediately on publication. Learn more about self-archiving and deposition of papers published OA.

E-Proofs

The Springer Nature e-proofing system is a unique solution that will enable authors to remotely edit /correct your article proofs.

The corresponding author will receive an e-mail containing a URL linking to the e-proofing site. Proof corrections must be returned within 48 hours of receipt. Failure to do so may result in delayed publication. Extensive corrections cannot be made at this stage.

For more information and instructions on how to use the e-proofing tool please see [here](#).

EDITORIAL POLICIES

Researchers should conduct their research – from research proposal to publication – in line with best practices and codes of conduct of relevant professional bodies and/or national and international regulatory bodies.

Springer Nature is committed to upholding the integrity of the scientific record. As a member of the [Committee on Publication Ethics](#) (COPE), *Experimental & Molecular Medicine* abides by COPE's principles on how to deal with potential acts of misconduct, which includes formal investigation of all perceived transgressions.

Changes to Authorship

It is the corresponding author's responsibility to ensure that the author list is correct at the point of first submission. Requests to change the authorship (such as to include or exclude an author, change an author's name or contribution) must be accompanied by a letter signed by all authors to show they concur with the change. New authors must also confirm that they fully comply with the journal's authorship requirements. Requests for addition or removal of authors as a result of authorship disputes (after acceptance) are honoured after formal notification by the institute or independent body and/or when there is agreement between all authors. Changes to the authorship will not be allowed once the manuscript has been accepted for publication.

Correspondence with the Journal

One author is designated the contact author for matters arising from the manuscript (materials requests, technical comments and so on). It is this author's responsibility to inform all co-authors of matters arising and to ensure such matters are dealt with promptly. Before submission, the corresponding author ensures that all authors are included in the author list, its order agreed upon by all authors, and are aware that the manuscript was submitted. After acceptance for publication, proofs are e-mailed to this corresponding author who should circulate the proof to all co-authors and coordinate corrections among them.

Duplicate & Redundant Publication

Papers must be original and not published or submitted for publication elsewhere. This rule also applies to non-English language publications.

Redundant publication (also described as "salami publishing") is when one study is split into several parts and submitted to two or more journals. It also includes findings that have previously been published elsewhere without proper cross-referencing, permission or justification. "Self-plagiarism" is considered a form of redundant publication as it concerns recycling or borrowing content from previous work without citation.

Springer Nature allows and encourages prior publication on recognized community preprint servers for review by other scientists before formal submission to a journal. The details of the preprint server concerned and any accession numbers should be included in the cover letter accompanying manuscript submission. This policy does not extend to preprints available to the media or that are otherwise publicized outside the scientific community before or during the submission and consideration process.

Plagiarism

Plagiarism is when an author attempts to pass off someone else's work as his or her own. Duplicate publication, sometimes called self-plagiarism, occurs when an author reuses substantial parts of his or her own published work without providing the appropriate references. Minor plagiarism without dishonest intent is relatively frequent, for example, when an author reuses parts of an introduction from an earlier paper. Overall similarity of less than 30% and similarity from a single source of less than 5% for a manuscript are considered for publication. Authors should rephrase the similar text and properly cite the original source to avoid plagiarism and copyright violation.

Springer Nature is a member of Similarity Check (formerly CrossCheck), a multi-publisher initiative used to screen published and submitted content for originality. *Experimental & Molecular Medicine* uses Similarity Check to detect instances of overlapping and similar text in submitted manuscripts. To find out more about CrossCheck visit <https://www.crossref.org/services/similarity-check/>

If a case of plagiarism comes to light after a paper is published, the Journal will conduct a preliminary investigation, utilising the guidelines of the [Committee on Publication Ethics](#). If plagiarism is proven, the Journal will contact the author's institute and funding agencies as appropriate. The paper containing the plagiarism may also be formally retracted or subject to correction.

Permissions

If a submission contains a figure that is published elsewhere or that is copyrighted, the authors must obtain written permission to reproduce the material in both print and electronic formats from the copyright owner and submit it with the manuscript. This follows for quotes, illustrations and other materials taken from previously published works not in the public domain. The original source should be cited in the figure caption or table footnote. A quote will be supplied upon acceptance of your paper.

Springer Nature endorses the toolkits and guidelines produced by the following bodies:

- Committee on Publication Ethics: <http://publicationethics.org/>

Pre- and Post-Submissions

Authors are welcome to post pre-submission versions or the original submitted version of the manuscript on a personal blog, a collaborative wiki or an institution-hosted repository at any time (but not subsequent pre-accept versions that evolve due to the Editorial process).

The published version – copyedited and in the individual Springer Nature journal format – may not be posted on any website or preprint server.

For content published under a creative commons license, authors can replace the submitted version with the final published version at publication as long as a publication reference and URL to the published version on the journal website are provided.

Conflict of Interest

In the interests of transparency and to help readers form their own judgments of potential bias, authors must declare whether or not there are any competing financial interests in relation to the work described. This information must be included in their cover letter and after the acknowledgements of their manuscript.

Authors submitting their manuscripts using the journal's online manuscript tracking system are required to make their declaration as part of this process and to specify the competing interests in cases where they exist, and should add COI statement to the end of the manuscript main text, and before the acknowledgement or the list of references. Please note that the disclosure is required only for the relationship that the author had within one year before the date of submission.

Referees are also requested to indicate any potential conflict they might have reviewing a particular paper.

In cases where the authors declare a competing financial interest, a statement to that effect is published as part of the article. If no such conflict exists, the statement will simply read that the authors have nothing to disclose.

The statement must contain an explicit and unambiguous statement describing any potential conflict of interest, or lack thereof, for any of the authors as it relates to the subject of the report. Examples include “Dr. Smith receives compensation as a consultant for XYZ Company,” “Dr. Jones and Dr. Smith have financial holdings in ABC Company,” or “Dr. Jones owns a patent on the diagnostic device described in this report.” These statements acknowledging or denying conflicts of interest must be included in the manuscript under the heading Conflict of Interest. The Conflict of Interest disclosure appears in the cover letter, in the manuscript submission process and before the References section in the manuscript.

It is difficult to specify a threshold at which a financial interest becomes significant, but note that many US universities require faculty members to disclose interests exceeding \$10,000 or 5% equity in a company. Any such figure is arbitrary, so “Declare all interests that could embarrass you were they to become publicly known after your work was published.” We do not consider diversified mutual funds or investment trusts to constitute a competing financial interest.

Clinical Trials

As defined by the International Committee of Medical Journal Editors (ICMJE), a clinical trial is any research project that prospectively assigns human subjects to intervention and comparison groups to study the cause-and-effect relationship between a medical intervention and a health outcome. A medical intervention is any intervention used to modify a health outcome and includes but is not limited to drugs, surgical procedures, devices, behavioural treatments, and process-of-care changes. A trial must have at least one prospectively assigned concurrent control or comparison group in order to trigger the requirement for registration.

Nonrandomized trials are not exempt from the registration requirement if they meet the above criteria.

When reporting experiments on human subjects, indicate whether the procedures were in accordance with the ethical standards of the responsible committee on human experimentation (institutional or regional) or with the Helsinki Declaration of 1975 (as revised in 1983). Include Institutional Review Board or Animal Care and Use Committee approvals. Where appropriate, clinical and epidemiologic studies should be analyzed to see if there is an effect of sex or any of the major ethnic groups. If there is no effect, it should be so stated in Results.

All clinical trials must be registered in a public registry prior to submission. *Experimental & Molecular Medicine* follows the trials registration policy of the ICMJE (www.icmje.org) and considers only trials that have been appropriately registered before submission, regardless of when the trial closed to enrolment. Acceptable registries must meet the following ICMJE requirements:

- be publicly available, searchable, and open to all prospective registrants
- have a validation mechanism for registration data
- be managed by a not-for-profit organization

Examples of registries that meet these criteria include (1) the registry sponsored by the United States National Library of Medicine (www.clinicaltrials.gov); (2) the International Standard Randomised Controlled Trial Number Registry (www.controlled-trials.com); (3) the Cochrane Renal Group Registry (www.cochrane-renal.org/trialsubmissionform.php); (4) the UK Clinical Research Network Portfolio (<http://public.ukcrn.org.uk>); (5) the European Clinical Trials Database (www.eudract.emea.eu.int); and (6) the Australian New Zealand Clinical Trials Registry (www.anzctr.org.au).

Springer Nature endorses the toolkits and guidelines produced by the following bodies:

- Committee on Publication Ethics: www.publicationethics.org
- Good Publication Practice: <http://www.ismpp.org/gpp3>
- Medical Publishing Insights and Practices Initiative: <https://www.mpip-initiative.org/toolkit.html>

Ethical Considerations

For primary research manuscripts reporting experiments on live vertebrates and/or higher invertebrates, the corresponding author must confirm that all experiments were performed in accordance with relevant guidelines and regulations.

Manuscripts should contain a statement to the effect that all human studies have been reviewed by the appropriate ethics committee or it should be stated clearly in the text that all persons gave their informed consent prior to their inclusion in the study. Details that might disclose the identity of the subjects under study should be omitted.

Authors should refer to the Medical Ethics Manual of the World Medical Association for further details.

(WMA, 2005, <https://www.wma.net/what-we-do/education/medical-ethics-manual/>).

When reporting the results from experiments on animals indicate whether the experiments were conducted according to the National Research Council's guidelines. Indicate the grade of the animals and give the certificate number of the animal breeder. Rats and mice of at least Grade II can be reported. The sex, age, and measured body weights of tested animals or humans should be expressed as mean, standard deviation, and total range.

Animal Studies in Ethical Considerations

The species, strain, sex, age, body weights, supplier, and number of tested animals used in total and for individual experiments must be indicated. Details of housing and husbandry must be included where they are likely to influence experimental results.

Biosecurity Policy

The Editors may also seek advice about submitted papers that raise other ethical concerns. These may include, for example, ethical issues or issues of data or materials access. Very occasionally, concerns may also relate to the implications of publishing a paper to the society, including threats to security. In such circumstances, advice will usually be sought simultaneously with the technical peer-review process. As in all publishing decisions, the decision whether to publish is at the discretion of the Editors.

Data Fabrication & Falsification

Falsification is the practice of altering research data with the intention of giving a false impression. This includes, but is not limited to, manipulating images, removing outliers or "inconvenient" results, or changing, adding or omitting data points. Fabrication is the practice of inventing data or results and recording and/or reporting them in the research record. Data falsification and fabrication call into question the integrity and credibility of data and the data record, and as such, they are among the most serious issues in scientific ethics.

Some manipulation of images is allowed to improve them for readability. Proper technical manipulation includes adjusting the contrast and/or brightness or colour balance if it is applied to the complete digital image (not parts of the image). The author should notify the Editor in the cover letter of any technical manipulation. Improper technical manipulation refers to obscuring, enhancing, deleting and/or introducing new elements into an image. See Image Integrity & Standards below for more details.

Misconduct

Springer Nature takes seriously all allegations of potential misconduct. As a member of the [Committee on Publication Ethics](#) (COPE), Experimental & Molecular Medicine will follow the COPE guidelines outlining how to deal with cases of suspected misconduct. As part of the investigation, the journal may opt to do one or more of the following:

- suspend review or publication of a paper until the issue has been investigated and resolved;
- request additional information from the author, including original data or images or ethics committee or IRB approval;
- make inquiries of other titles believed to be affected;
- forward concerns to the author's employer or person responsible for research governance at the author's institution;
- refer the matter to other authorities or regulatory bodies (for example, the Office of Research Integrity in the US or the General Medical Council in the UK); or
- submit the case to COPE in an anonymized form for additional guidance on resolution.

Please note that, in keeping with the journal's policy of the confidentiality of peer review, if sharing of information with third parties is necessary, disclosure will be made to only those Editors who the Editor believes may have information that is pertinent to the case, and the amount of information will be limited to the minimum required.

Anonymity and Confidentiality

Editors, authors and reviewers are required to keep confidential all details of the editorial and peer review process on submitted manuscripts. Unless otherwise declared as a part of open peer review, the peer review process is confidential and conducted anonymously. All details about submitted manuscripts are kept confidential and no comments are issued to outside parties or organizations about manuscripts under consideration or if they are rejected. Editors are restricted to making public comments on a published article's content and their evaluation.

Upon accepting an invitation to evaluate a manuscript, reviewers must keep the manuscript and associated data confidential, and not redistribute them without the journal's permission. If a reviewer asks a colleague to assist in assessing a manuscript, confidentiality must be ensured and their names must be provided to the journal with the final report.

We ask reviewers not to identify themselves to authors without the editor's knowledge. If they wish to reveal their identities while the manuscript is under consideration, this should be done via the editor; if this is not practicable, we ask authors to inform the editor as soon as possible after the reviewer has revealed their identity. Our own policy is to neither confirm nor deny any speculation about reviewers' identities, and we encourage reviewers to adopt a similar policy.

We deplore any attempt by authors to confront reviewers or try to determine their identities. Reviewers should be aware that it is our policy to keep their names confidential and that we do our utmost to ensure this confidentiality. We cannot, however, guarantee to maintain this confidentiality in the face of a successful legal action to disclose identity.

Regardless of whether a submitted manuscript is eventually published, correspondence with the journal, referees' reports, and other confidential material must not be published, disclosed, or otherwise publicised without prior written consent.

Communication with the Media

Material submitted must not be discussed with the media. We reserve the right to halt the consideration or publication of a paper if this condition is broken. If a paper is particularly newsworthy, the press release will be sent to our list of journalists in advance of publication with an embargo that forbids any coverage of the manuscript, or the findings of the manuscript, until the time and date clearly stated. Authors whose papers are scheduled for publication may also arrange their own publicity (for instance through their institution's press offices), but they must strictly adhere to our press embargo and are advised to coordinate their own publicity with our press office.

Communication between Scientists

We do not wish to hinder communication between scientists. We ask you to communicate with other researchers as much as you wish, whether on a recognized community preprint server, by discussion at scientific meetings or by online collaborative sites such as wikis, but we do not encourage premature publication by discussion with the press (beyond a formal presentation, if at a conference).

Peer Review

Manuscripts sent out for peer review are evaluated by two or more independent reviewer. Authors are welcome to suggest independent reviewers to evaluate their manuscript, as well as request individuals or laboratories. All recommendations are considered, but it is at the Editor's discretion their choice of reviewers. To expedite the review process, only papers that seem most likely to meet Editorial criteria are sent for external review. Papers judged by the editors to be of insufficient general interest or otherwise inappropriate are rejected promptly without external review. The editors then make a decision based on the reviewers' evaluations:

- **Accept**, with or without Editorial revisions.
- **Revise**, with the author addressing concerns raised by the reviewers before a final decision is reached.
- **Reject**, typically on grounds of specialist interest, lack of novelty, insufficient conceptual advance or major technical and/or interpretational problems.

Selecting Peer Reviewers

Reviewer selection is critical to the publication process, and we base our choice on many factors, based on expertise, reputation, and specific recommendations. A reviewer may decline the invitation to evaluate a manuscript where there is a perceived conflict of interest (financial or otherwise).

Reviewers' identities are not released to authors, except when reviewers specifically ask to be identified. If reviewers wish to reveal their identities while the manuscript is under consideration, this should be done through the Editor. Should a reviewer contact an author directly, we ask authors to inform the Editor as soon as possible. We prohibit any attempt by authors to confront reviewers or determine their identities. Our own policy is to neither confirm nor deny any speculation about reviewers' identities, and we encourage reviewers to adopt a similar policy.

Correction and Retraction Process

Once the paper is published online it is considered final and cannot be amended. The online version is part of the published record hence the original version must be preserved and changes to the paper should be made as a formal correction.

Please note the following categories of corrections to print and online versions of peer reviewed content:

- **Publisher Correction.** Notification of **an important error made by the journal** that affects the publication record or the scientific integrity of the paper, or the reputation of the authors, or of the journal.
- **Author Correction.** Notification of **an important error made by the author(s)** that affects the publication record or the scientific integrity of the paper, or the reputation of the authors or the journal.
- **Retraction.** Notification of **invalid results**. All co-authors must sign a retraction specifying the error and stating briefly how the conclusions are affected.

Decisions about corrections are made by the Editor (sometimes with peer reviewers' advice) and this sometimes involves author consultation. Requests to make corrections that do not affect the paper in a significant way or impair the reader's understanding of the contribution (a spelling mistake or grammatical error, for example) are not considered.

In cases where co-authors disagree about a correction, the editors will take advice from independent peer reviewers and impose the appropriate correction, noting the dissenting author(s) in the text of the published version.

Please also see [authors & referees page](#) for detailed information about publication policies of the Nature Research journals. *Experimental & Molecular Medicine*, share a number of [common policies](#) with these journals including the following:

[Author responsibilities](#)

[Licence agreement and author copyright](#)

[Embargo policy and press releases](#)

[Use of experimental animals and human subjects](#)

[Competing financial interests](#)

[Availability of materials and data](#)

[Digital image integrity and standards](#)

[Biosecurity concerns](#)

[Refutations, complaints and corrections](#)

[Duplicate publication](#)

[Confidentiality and pre-publicity](#)

[Plagiarism and fabrication](#)

FURTHER INFORMATION

For inquiries related to submission requirements, please contact the [editorial office \(ksbmb3@ksbmb.or.kr\)](mailto:ksbmb3@ksbmb.or.kr). For inquiries related to advertising, permissions, papers in production or publishing a supplement, please contact the [publisher's office](#).